| 1 |
34935105 | Opicapone for the Treatment of Parkinson's Disease "Off" Episodes: Pharmacology and Clinical Considerations. | 2022 Feb |
1 |
| 2 |
34962574 | Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial. | 2022 Feb 1 |
2 |
| 3 |
35180134 | Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. | 2022 |
2 |
| 4 |
35217995 | COMT Inhibitors in the Management of Parkinson's Disease. | 2022 Mar |
1 |
| 5 |
35563817 | Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients. | 2022 Apr 30 |
2 |
| 6 |
35603896 | Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinson's Disease: A Meta-Analysis and Systematic Review. | 2022 May 22 |
1 |
| 7 |
32108308 | Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase. | 2021 May |
4 |
| 8 |
33136226 | Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone. | 2021 Jan |
4 |
| 9 |
33220276 | Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys. | 2021 Feb 5 |
1 |
| 10 |
33840171 | In silico discovery and evaluation of phytochemicals binding mechanism against human catechol-O-methyltransferase as a putative bioenhancer of L-DOPA therapy in Parkinson disease. | 2021 Mar |
3 |
| 11 |
34007239 | Clinical Utility of Opicapone in the Management of Parkinson's Disease: A Short Review on Emerging Data and Place in Therapy. | 2021 |
4 |
| 12 |
34225162 | The inhibition of catechol O-methyltransferase and monoamine oxidase by tetralone and indanone derivatives substituted with the nitrocatechol moiety. | 2021 Sep |
1 |
| 13 |
34346015 | Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson's disease-a meta-analysis. | 2021 Oct |
2 |
| 14 |
34525893 | Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone. | 2021 Sep |
2 |
| 15 |
34630283 | Different Catechol-O-Methyl Transferase Inhibitors in Parkinson's Disease: A Bayesian Network Meta-Analysis. | 2021 |
2 |
| 16 |
32238065 | Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease. | 2020 May |
1 |
| 17 |
32450711 | The preclinical discovery and development of opicapone for the treatment of Parkinson's disease. | 2020 Sep |
3 |
| 18 |
32515486 | Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts. | 2020 Jun 12 |
1 |
| 19 |
32533012 | Genetic variations in catechol-O-methyltransferase gene are associated with levodopa response variability in Chinese patients with Parkinson's disease. | 2020 Jun 12 |
2 |
| 20 |
32588409 | [The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease]. | 2020 Sep |
1 |
| 21 |
33093598 | Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. | 2020 Oct 22 |
3 |
| 22 |
33151475 | Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study. | 2020 Nov |
1 |
| 23 |
33352833 | Entacapone Treatment Modulates Hippocampal Proteins Related to Synaptic Vehicle Trafficking. | 2020 Dec 18 |
1 |
| 24 |
31258092 | Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase. | 2019 |
4 |
| 25 |
31829066 | Bioavailability and Neuroprotectivity of 3-(3, 4-dimethoxy phenyl)-1-4 (methoxy phenyl) prop-2-en-1-one against Schizophrenia: an in silico approach. | 2019 Oct-Dec |
1 |
| 26 |
29345156 | Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease. | 2018 Mar |
3 |
| 27 |
29578580 | MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease. | 2018 Jul |
3 |
| 28 |
29614697 | Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review. | 2018 |
2 |
| 29 |
29670409 | Safinamide: an add-on treatment for managing Parkinson's disease. | 2018 |
1 |
| 30 |
29697034 | Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase. | 2018 |
7 |
| 31 |
30075828 | Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia. | 2018 |
2 |
| 32 |
30290160 | Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration. | 2018 Dec |
1 |
| 33 |
27763682 | Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics. | 2017 Mar |
1 |
| 34 |
28027332 | Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. | 2017 Feb 1 |
2 |
| 35 |
28234566 | Opicapone for the treatment of Parkinson's disease. | 2017 Mar |
2 |
| 36 |
28315782 | Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice. | 2017 Jun |
1 |
| 37 |
28580819 | Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. | 2017 Jul |
2 |
| 38 |
30566298 | The therapy of the motor symptoms in the advanced stage of Parkinson's disease. | 2017 Jan |
1 |
| 39 |
26293352 | Modern treatment in Parkinson's disease, a personal approach. | 2016 Jan |
1 |
| 40 |
27129930 | Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition. | 2016 Jun |
1 |
| 41 |
27163503 | Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. | 2016 May |
1 |
| 42 |
27456338 | 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA. | 2016 Jul 25 |
4 |
| 43 |
27493964 | Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective? | 2016 |
3 |
| 44 |
27653922 | Catechol-O-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson's disease. | 2016 Oct 15 |
1 |
| 45 |
27685665 | Design of Potent and Druglike Nonphenolic Inhibitors for Catechol O-Methyltransferase Derived from a Fragment Screening Approach Targeting the S-Adenosyl-l-methionine Pocket. | 2016 Nov 23 |
1 |
| 46 |
25409768 | Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. | 2015 Apr |
2 |
| 47 |
25476691 | Novel formulations and modes of delivery of levodopa. | 2015 Jan |
1 |
| 48 |
25510857 | Multilevel impact of the dopamine system on the emotion-potentiated startle reflex. | 2015 Jun |
3 |
| 49 |
25559423 | Catechol-O-methyltransferase inhibitors in Parkinson's disease. | 2015 Feb |
4 |
| 50 |
25649051 | Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. | 2015 May |
3 |